Telomerase activity is associated with cell cycle deregulation in human breast cancer

Cancer Research

Volumn 57, Issue 3, 1997, Pages 549-554

  Landberg, Göran ^a   Nielsen, Niels Hilmer ^a   Nilsson, Pia ^a   Emdin, Stefan O ^a   Cajander, Jenny ^a   Roos, Göran ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN E; KI 67 ANTIGEN; PROTEIN P16; RETINOBLASTOMA PROTEIN; TELOMERASE;

ARTICLE; BREAST CANCER; CANCER GROWTH; CELL CYCLE; CELL IMMORTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

BREAST NEOPLASMS; CARRIER PROTEINS; CELL CYCLE; CELL DIVISION; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLINS; FEMALE; HUMANS; ONCOGENE PROTEINS; RETINOBLASTOMA PROTEIN; TELOMERASE;

EID: 0031050924     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Harley, C. B., Futcher, A. B., and Greider, C. W. Telomeres shorten during ageing of human fibroblasts. Nature (Lond.), 345: 458-460, 1990.
2. Allsopp, R. C., Vaziri, H., Patterson, C., Goldstein, S., Younglai, E. V., Futcher, A. B., Greider, C. W., and Harley, C. B. Telomere length predicts replicative capacity of human fibroblasts. Proc. Natl. Acad. Sci. USA, 89: 10114-10118, 1992.
3. Allsopp, R. C., and Harley, C. B. Evidence for a critical telomere length in senescent human fibroblasts. Exp. Cell Res., 219: 130-136, 1995.
4. von Zglinicki, T., Saretzki, G., Döcke, W., and Lotze, C. Mild hyperoxia shortens telomeres and inhibits proliferation of fibroblasts: a model for senescence? Exp. Cell Res., 220: 186-193, 1995.
5. Vaziri, H., and Benchimol, S. From telomere loss to p53 induction and activation of a DNA-damage pathway at senescence: the telomere loss/DNA damage model of cell aging. Exp. Gerontol., 31: 295-301, 1996.
6. Bond, J. A., Wyllie, F. S. and Wynford-Thomas, D. Escape from senescence in human diploid fibroblasts induced directly by mutant p53. Oncogene, 9: 1885-1889, 1994.
7. Rogan, E. M., Bryan, T. M., Hukku, B., Maclean, K., Chang, A. C., Moy, E. L., Englezou, A., Warneford, S. G., Dalla-Pozza, L., and Reddel, R. R. Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol. Cell. Biol., 15: 4745-4753, 1995.
8. Shay, J. W., and Wright, W. E. Both Rb and p53 are potential regulators of human cellular senescence. In: M. L. Brandi and R. White (eds.), Hereditary Tumors, pp. 173-182. New York: Raven Press, 1991.
9. Shay, J. W., Wright, W. E., and Werbin, H. Defining the molecular mechanisms of human cell immortalization. Biochem. Biophys. Acta, 1072: 1-7, 1991.
10. Bunn, C. L., and Tarrant, G. M. Limited lifespan in somatic cell hybrids and cybrids. Exp. Cell Res., 127: 385-396, 1980.
11. Greider, C. W., and Blackburn, E. H. Identification of a specific telomere terminal transferase activity in tetrahymena extracts. Cell, 43: 405-413, 1985.
12. Morin, G. B. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell, 59: 521-529, 1989.
13. Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., and Shay, J. W. Specific association of human telomerase activity with immortal cells and cancer. Science (Washington DC), 266: 2011-2015, 1994.
14. Murnane, J. P., Sabatier, L., Marder, B. A., and Morgan, W. F. Telomere dynamics in an immortal human cell line. EMBO J., 13: 4953-4962, 1994.
15. Bryan, M. T., Englezou, A., Gupta, J., Bacchetti, S., and Reddel, R. R. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J., 14: 4240-4248, 1995.
16. Strahl, C., and Blackburn, E. H. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol. Cell. Biol., 16: 53-65, 1996.
17. Counter, C. M., Hirte, H. W., Bacchetti, S., and Harley, C. B. Telomerase activity in human ovarian carcinoma. Proc. Natl. Acad. Sci. USA, 91: 2900-2904, 1994.
18. Nilsson, P., Mehle, C., Remes, K., and Roos, G. Telomerase activity in vitro in human malignant hematopoietic cells. Oncogene, 9: 3043-3048, 1994.
19. Bacchetti, S., and Counter, C. M. Telomeres and telomerase in human cancer. Int. J. Oncol., 7: 423-432, 1995.
20. Hiyama, E., Gollahon, L., Kataoka, T., Kuroi, K., Yokoyama, T., Gazdar, A. F., Hiyama, K., Piatyszek, M. A., and Shay, J. W. Telomerase activity in human breast carcinoma. J. Natl. Cancer Inst., 88: 116-122, 1996.
21. Langford, L. A., Piatyszek, M. A., Xu, R. S., Schold, S. C., and Shay, J. W. Telomerase activity in human brain tumors. Lancet, 346: 1267-1268, 1995.
22. Tahara, H., Nakanishi, T., Kitamoto, M., Nakashio, R., Shay, J. W., Tahara, E., Kajiyama, G., and Ide, T. Telomerase activity in human liver tissues: comparison between chronic liver disease and hepatocellular carcinomas. Cancer Res., 55: 2734-2736, 1995.
23. Sommerfeld, H. J., Meeker, A. K., Piatyszek, M. A., Bova, G. S., Shay, J. W., and Coffey, D. S. Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res., 56: 218-222, 1996.
24. Mehle, C., Piatyszek, M. A., Ljungberg, B., Shay, J. W., and Roos, G. Telomerase activity in human renal cell carcinoma. Oncogene, 13: 161-166, 1996.
25. Hiyama, K., Hirai, Y., Kyoizumi, S., Akiyama, M., Hiyama, E., Piatyszek, M. A., Shay, J. W., Ishioka, S., and Yamakido, M. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J. Immunol., 755: 3711-3715, 1995.
26. Norrback, K-F., Dahlenborg, K., Carlsson, R., and Roos, G. Telomerase activation in normal B lymphocytes and non-Hodgkin's lymphomas. Blood, 88: 222-229, 1996.
27. Sharma, H. W., Sokoloski, J. A., Perez, J. R., Maltese, J. Y., Sartorelli, A C., Stein, C. A., Nochols, G., Khaled, Z., Telang, N. T. Narayanan, R. Differentiation of immortal cells inhibits telomerese activity. Proc. Natl. Acad. Sci. USA, 92: 12343-12346, 1995.
28. Holt, S. E., Wright, W. E., and Shay, J. W. Regulation of telomerase activity in immortal cell lines. Mol. Cell Biol., 16: 2932-2939, 1996.
29. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
30. Pines, J. Cyclins, CDKs and cancer. Semin. Cancer Biol., 6: 63-72, 1995.
31. 1 control. Cancer Res., 55: 4818-4822, 1995.
32. Borg, A., Sigurdsson, H., Clark, G. M., Freno, M., Fuqua, S. A. W., Olsson, H., Killander, D., and McGurie, W. L. Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. Br. J. Cancer. 63: 136-142, 1991.
33. Gillet, C., Smith, P., Gregory, W., Richards, M., Millis, R., Peters, G., and Barnes, D. Cyclin D1 and prognosis in human breast cancer. Int. J. Cancer, 69: 92-99, 1996.
34. Keyomarsi, K., O'Leary, N., Molnar, G., Lees, E., Fingert, H. J., and Pardee, A. B. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res., 54: 380-385, 1994.
35. Keyomarsi, K., Conte, D., Jr., Toyofuku, W., and Fox, P. Deregulation of cyclin E in breast cancer. Oncogene, 11: 941-950, 1995.
36. Nielsen, N. H., Amerlöv, C., Emdin, S. O., and Landberg, G. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br. J. Cancer, 74: 874-880, 1996.
37. Wimmel, A., Lucibello, F. C., Sewing, A., Adolphs, S., and Müller, R. Inducible . acceleration of G1 progression through tetracycline-regulated expression of human cyclin E. Oncogene, 9: 995-997, 1994.
38. Ohtsubo, M., Theodoras, A. M., Schumacher, J., Roberts, J. M., and Pagano, M. Human cyclin E, a nuclear protein essential for the G1- to S-phase transition. Mol. Cell. Biol., 75: 2612-2624, 1995.
39. Hiyama, K., Ishioka, S., Shirotani, Y., Inai, K., Hiyama, E., Murakami, I., Isobe, T., Inamizu, T., and Yamakido, M. Alterations in telomeric repeat length in lung cancer are associated with loss of heterozygosity in p53 and Rb. Oncogene, 10: 937-944, 1995.
40. Whitaker, N. J., Bryan, T. M., Bonnefm, P., Chang, A. C., Musgrove, E. A., Braithwaite, A. W., and Reddel, R. R. Involvement of RB-1, p53, p16INK4 and telomerase in immortalisation of human cells. Oncogene, 11: 971-976, 1995.
41. Sugino, T., Yoshida, K., Bolodeoku, J., Tahara, H., Buley, I., Manek, S., Wells, C., Goodison, S., Ide, T., Suzuli, T., Tahara, E., and Tarin, D. Telomerase activity in human breast cancer and benign breast lesions: diagnostic applications in clinical specimens including fine needle aspirates. Int. J. Cancer, 69: 301-306, 1996.
42. Piatyszek, M. A., Kim, N. W., Weinrich, S. L., Hiyama, K., Hiyama, E., Wright, W. E., and Shay, J. W. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Sci., 17: 1-5, 1995.
43. Wright, W. E., Shay, J. W., and Piatyszek, M. A. Modifications of a telomeric repeat amplification protocol (TRAP) results in increased reliability, linearity and sensitivity. Nucleic Acids Res., 23: 3794-3795, 1995.
44. Taylor, S. T., Ramirez, R. D., Ogoshi, M., Chaffins, M., Piatyszek, M. A., and Shay, J. W. Detection of telomerase activity in malignant and nonmalignant skin disorders. J. Invest. Dermatol., 106: 759-765, 1996.
45. Shay, J. W., Wright, W. E., and Werbin, H. Toward a molecular understanding of human breast cancer: a hypothesis. Breast Cancer Res. Treat., 25: 83-94, 1993.
46. Sawan, A., Randall, B., Angus, B., Wright, C., Henry, J. A., Ostrowski, J., Hennessy, C., Leonard, T. W. J., Corbett, I., and Home, C. H. W. J. Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: an imimmohistological study. J. Pathol., 168: 23-28, 1992.
47. Pietiläinen, T., Lipponen, P., Aaltomaa, S., Eskelinen, M., Kosma, V. M., and Syrjänen, K. Expression of retinoblastoma gene protein (Rb) in breast cancer as related to established prognostic factors and survival. Eur. J. Cancer, 31: 329-333, 1995.
48. Müller, H., Lukas, J., Schneider, A., Warthoe, P., Bartek, J., Eilers, M., and Strauss, M. Cyclin D1 expression is regulated by the retinoblastoma protein. Proc. Natl. Acad. Sci. USA, 91: 2945-2949, 1994.
49. ink4/MTS1 tumour suppressor gene product. EMBO J., 14: 503-511, 1995.
50. Nielsen, N. H., Emdin, S. O., Cajander, J., and Landberg, G. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene, in press, 1996.
51. Lovec, H., Sewing, A., Lucibello, F. C., Müller, H., and Möröy, T. Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. Oncogene, 9: 323-326, 1994.
52. Wang, J. Y. J., Knudsen, E. S., and Welch, P. J. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Adv. Cancer Res., 64: 25-85, 1994.
53. Michalides, R., Hageman, P., van Tineren, H., Houben, L., Wientjens, E., Klompmarker, R., and Peterse, J. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br. J. Cancer, 73: 728-734, 1996.
54. Ohtsubo, M., and Roberts, J. M. Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science (Washington DC), 26: 1908-1912, 1993.